A technology to ensure optimum cell performance for regenerative medicine
Lead Participant:
PLASTICELL LIMITED
Abstract
The central issue of regenerative medicine is the capacity to reproducibly control the differentiation of a high proportion of stem cells. Because this is inherently influenced by many biological, chemical and physical cues, a very large number of experimental tests are required in each instance to determine the optimum outcome. By adding the power of advanced imaging and robotic microwell-based engineering to an already powerful combinatorial technique the proposed programme will create an internationally leading general technology for quickly and efficiently examining large numbers of linked variables. In this way it will create foundations for a powerful commercial activity applicable across the whole of the new industry.
Lead Participant | Project Cost | Grant Offer |
---|---|---|
PLASTICELL LIMITED | £745,918 | £ 405,724 |
  | ||
Participant |
||
THE HEALTH PROTECTION AGENCY (HPA NIBSC) | £646,169 | £ 318,690 |
UNIVERSITY COLLEGE LONDON | £363,490 | £ 363,490 |
People |
ORCID iD |